← Back to Search

Home Blood Pressure Monitoring for High Blood Pressure (TB-HBPM Trial)

N/A

Recruiting

Led By Kevin Fiscella, MD, MPH

Research Sponsored by University of Rochester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Current HFM patient 18-85 years of age with hypertension diagnosis

Be older than 18 years old

Must not have

Diagnosis of dementia, end-stage renal disease, and/or in hospice

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 48 months participation

Awards & highlights

No Placebo-Only Group

Summary

This trial will help identify strategies for implementing and sustaining team-based home blood pressure monitoring (TB-HBPM) in primary care settings, in order to improve hypertension control rates.

Who is the study for?

This trial is for adults aged 18-85 with high blood pressure who are patients at participating practices. It includes practice employees involved in hypertensive patient care. People with dementia, end-stage renal disease, hospice care, or current pregnancy cannot join.

What is being tested?

The study tests a team-based home blood pressure monitoring program that lets patients send their readings to their health teams and receive coordinated hypertension care including education and monthly feedback.

What are the potential side effects?

Since this intervention involves monitoring and educational strategies rather than medication, it does not have the typical side effects associated with drug treatments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 85 years old with high blood pressure.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with dementia, end-stage renal disease, or am in hospice care.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ beginning with the 6-month intervention period and up to 48 months participation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~beginning with the 6-month intervention period and up to 48 months participation

This trial's timeline: 3 weeks for screening, Varies for treatment, and beginning with the 6-month intervention period and up to 48 months participation for reporting.